SANTA CLARA, Calif.--(BUSINESS WIRE)--AttackIQ®, the leading independent vendor of breach and attack simulation solutions and a founding research partner of the MITRE Engenuity Center for ...
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant ...
Researchers with the Johns Hopkins Kimmel Cancer Center, the Johns Hopkins University School of Medicine and four other institutions have developed a molecular test to identify the presence of brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results